Quest for the right Drug
דוקסילין 100 DOXYLIN 100 (DOXYCYCLINE AS HYCLATE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליה : TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Contraindications : התוויות נגד
4.3. Contraindications Hypersensitivity to doxycycline, or to any other tetracyclines or to any of the excipients listed in section 6.1. Obstructive oesophageal disorders, such as stricture or achalasia. The use of drugs of the tetracycline class during tooth development (pregnancy, infancy and childhood to the age of 12 years) may cause permanent discoloration of the teeth (yellow-grey-brown). This adverse reaction is more common during long-term use of the drugs but has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. Doxylin is therefore contraindicated in these groups of patients. Pregnancy Doxylin is contraindicated in pregnancy. It appears that the risks associated with the use of tetracyclines during pregnancy are predominantly due to effects on teeth and skeletal development (See section 4.4 regarding use during tooth development). Nursing mothers Tetracyclines are excreted into milk and are therefore contraindicated in nursing mothers (See section 4.4 regarding use during tooth development). Paediatric population Doxylin is contraindicated in children under the age of 12 years. As with other tetracyclines, Doxylin forms a stable calcium complex in any bone-forming tissue. A decrease in the fibula growth rate has been observed in prematures given oral tetracyclines in doses of 25 mg/kg every 6 hours. This reaction was shown to be reversible when the drug was discontinued. (See above about use during tooth development).
שימוש לפי פנקס קופ''ח כללית 1994
Respiratory, urogenital & gastorintestinal infections caused by: rickettsiae, chlamydia group, mycoplasma pneumoniae, yersinia, vibrio cholera, h. influenzae, n. gonorrhea, t. pallidum, borrelia recurrentis, brucella. Malaria resistant to chrloroquine
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה שאושרה לשימוש כללי בקופ'ח
מידע נוסף
